calibrated to 1.1% population-level MG prevalence. We modelled the potential impact of using the ResistancePlus MG test (SpeeDx; Sydney, Australia) for symptomatic patients. We conducted sensitivity analyses varying the clearance rate (23–44 days) and percent of infections that are asymptomatic in women (0%–11.7%).

**Results** The model estimated a per-partner MG transmission probability of 0.042. The model predicted that implementing the ResistancePlus test for symptomatic patients would increase the percent of MG infections that are macrolide-susceptible from 50% to 85% in 2 years. In sensitivity analyses, transmission probability estimates and 2 year percent of MG infections that are macrolide-susceptible varied from 0.032–0.047 and 82%–92%, respectively.

**Conclusion** Directing treatment based on aetiology and known macrolide resistance may preserve the ability to treat MG with azithromycin.莫西沙星治疗可能有限制，因为它需要在患者中检测到已知macrolide-resistant MG和预防治疗前的管理。

**Methods** Anorectal GC/CT infections were diagnosed at baseline among 698 MSM enrolled in the Anza Matema study in Kisumu, Kenya. Multivariable logistic regression was used to identify associations with asymptomatic GC/CT anorectal infection. We derived a total risk score (range: 0–5) for each participant using the coefficients of the final multivariable model. Risk score algorithm performance was compared to WHO algorithm performance with respect to sensitivity, specificity, and number needed to treat (NNT).

**Results** Asymptomatic GC/CT anorectal infection prevalence was 4.2%. Predictors and corresponding risk scores were: HIV infection (2), age 18–24 years (2), and unprotected anal sex (1). A risk score ≥3 was 83% sensitive and 65% specific in detecting asymptomatic GC/CT anorectal infection. In contrast, the WHO PT algorithm had low sensitivity (25%), but was 84% specific. While 37% of asymptomatic participants met PT eligibility criteria using a risk score ≥3, only 17% met eligibility by WHO PT criteria. Using our risk score algorithm, 12 participants would need PT to treat one GC/CT anorectal infection, compared to 38 participants by WHO criteria.

**Conclusion** An empiric risk score based on age, HIV status, and unprotected anal sex improved both sensitivity and efficiency (i.e., NNT) of identification of asymptomatic GC/CT anorectal infection, compared to the WHO PT algorithm. If validated in other settings, this risk score could improve the management of asymptomatic GC/CT anorectal infections in settings where diagnostic testing is not available.

**P3.132 PROJECTING THE EPIDEMIOLOGICAL EFFECT, COST-EFFECTIVENESS AND TRANSMISSION OF HIV DRUG RESISTANCE IN VIETNAM ASSOCIATED WITH VIRAL LOAD MONITORING STRATEGIES**

Lei Zhang, Melbourne Sexual Health Centre, Melbourne, Australia

10.1136/sextrans-2017-053264.367

**Introduction** Objectives: The objective of this study was to investigate the potential epidemiological impact of viral load (VL) monitoring and its cost-effectiveness in Vietnam, where transmitted HIV drug resistance (TDR) prevalence has increased from 5% to 5%–15% in the past decade.

**Methods** Using a population-based mathematical model driven by data from Vietnam, we simulated scenarios of various combinations of VL testing coverage, VL thresholds for second-line ART initiation and availability of HIV drug-resistance tests. We assessed the cost per disability-adjusted life year (DALY) averted for each scenario.

**Results** Projecting expected ART scale-up levels, to approximately double the number of people on ART by 2030, will lead to an estimated 9120–34600 cases of TDR and 55180 cases (95% CI: 40540–65900 cases) of acquired drug resistance (ADR) in the absence of VL monitoring. This projection corresponds to a TDR prevalence of 16% (95% CI: 11%–24%) and ADR of 18% (95% CI: 15%–20%). Annual or biennial VL monitoring with 30% coverage is expected to relieve 12%–31% of TDR (2260–5860 cases), 25%–59% of ADR (9620–22650 cases), and 2%–6% of HIV-related deaths (360–880 cases) and 19270–51400 DALYs during 2015–30. The 30% coverage of VL monitoring is estimated to cost US$4848–5154 per DALY averted. The projected additional cost for implementing this strategy is US $105–268 million over 2015–30.

**Conclusion** Our study suggests that a programmatically achievable 30% coverage of VL monitoring can have considerable benefits for individuals and leads to population health benefits by reducing the overall national burden of HIV drug resistance. It is marginally cost-effective according to common willingness-to-pay thresholds.

**P3.133 EVALUATION OF PRODUCTION AND LYTIC CAPACITY OF VAGINOLYSIN PRODUCED BY BIOTYPES OF GARDNERELLA VAGINALIS**


10.1136/sextrans-2017-053264.368

**Introduction:** Gardnerella vaginalis is the main etiological agent of bacterial vaginosis (BV), this bacteria has been classified in eight biotypes based on the production of beta-galactosidase, hydrolysis of hippurate and lipase, additionally produces several virulence factors, among them vaginolysin (VLY) is the most important. VLY is a pore-forming cytolysin that damages cells structurally and functionally through the